Intravesical CAR T therapy opens door to bladder-sparing cancer treatment

Intravesical CAR T therapy opens door to bladder-sparing cancer treatment. Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The study, published in the Journal of Experimental Medicine (JEM), demonstrates that direct delivery of these CAR T cells via a catheter can control bladder tumors in mice, raising hopes that a similar approach may be effective in humans.

• Ponto de atenção: intravesical.
• Ponto de atenção: therapy.
• Ponto de atenção: opens.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.